Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencing

References

• Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24;352(8):786–792. doi: 10.1056/NEJMoa044238
   PubMed Web of Science ®Google Scholar
• Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discovery. 2014 Sep;4(9):1046–1061.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-Positive lung cancer. N Engl J Med. 2017 Feb 16;376(7):629–640. doi: 10.1056/NEJMoa1612674
   PubMed Web of Science ®Google Scholar
• Shi Y, Hu X, Zhang S, et al. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respir Med. 2021 Aug;9(8):829–839.
   PubMed Web of Science ®Google Scholar
• Lu S, Wang Q, Zhang G, et al. Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790M+ NSCLC: updated post-national medical products administration approval results from the APOLLO registrational trial. J Thorac Oncol. 2022 Mar;17(3):411–422.
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American pathologists, the international Association for the study of lung cancer, and the association for molecular pathology. Arch Pathol Lab Med. 2018 Mar;142(3):321–346.
   PubMed Web of Science ®Google Scholar
• Li C, He Q, Liang H, et al. Diagnostic accuracy of droplet digital PCR and amplification refractory mutation system PCR for detecting EGFR mutation in cell-free DNA of lung cancer: a meta-analysis. Front Oncol. 2020;10:290. doi: 10.3389/fonc.2020.00290
   PubMed Web of Science ®Google Scholar
• Thress KS, Brant R, Carr TH, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung cancer. 2015 Dec;90(3):509–515.
   PubMed Web of Science ®Google Scholar
• Guo QM, Wang L, Yu WJ, et al. Detection of plasma EGFR mutations in NSCLC patients with a validated ddPCR lung cfDNA assay. J Cancer. 2019;10(18):4341–4349. doi: 10.7150/jca.31326
   PubMed Web of Science ®Google Scholar
• Li C, Jia R, Liu H, et al. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors. Diagn Pathol. 2018 Aug 13;13(1):49. doi: 10.1186/s13000-018-0728-6
   PubMedGoogle Scholar
• Wang W, Song Z, Zhang Y. A comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance. Cancer Med. 2017 Jan;6(1):154–162. doi:10.1002/cam4.978
   PubMed Web of Science ®Google Scholar
• Vendrell JA, Quantin X, Aussel A, et al. EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome. Transl Lung Cancer Res. 2021 Nov;10(11):4084–4094.
   PubMed Web of Science ®Google Scholar
• Guibert N, Hu Y, Feeney N, et al. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. Ann Oncol. 2018 Apr 1;29(4):1049–1055. doi: 10.1093/annonc/mdy005
   PubMed Web of Science ®Google Scholar
• Zhu G, Ye X, Dong Z, et al. Highly sensitive droplet digital PCR method for detection of EGFR-Activating mutations in plasma cell-free DNA from patients with advanced non-small Cell lung cancer. J Mol Diagn. 2015 May;17(3):265–272.
   PubMed Web of Science ®Google Scholar
• Xu Z, Hao X, Wang Q, et al. Efficacy of osimertinib after progression of first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR-Mutated lung adenocarcinoma: a real-world study in Chinese patients. Cancer Manage Res. 2022;14:863–873. doi: 10.2147/CMAR.S346173
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, National Cancer Institute of Canada. JNCI. 2000 Feb 2;92(3):205–216. doi: 10.1093/jnci/92.3.205
   PubMedGoogle Scholar
• Li Y, Zhang T, Zhang J, et al. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants. Lung cancer. 2018 Apr;118:128–133. doi: 10.1016/j.lungcan.2018.01.026
   PubMed Web of Science ®Google Scholar
• Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 May;17(5):577–589.
   PubMed Web of Science ®Google Scholar
• Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1454–1466.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Ostoros G, Cobo M, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014 Sep;9(9):1345–1353.
   PubMed Web of Science ®Google Scholar
• Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010 Jan 19;17(1):77–88. doi: 10.1016/j.ccr.2009.11.022
   PubMed Web of Science ®Google Scholar
• Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1689–1699. doi: 10.1056/NEJMoa1411817
   PubMed Web of Science ®Google Scholar
• Eide IJZ, Helland Å, Ekman S, et al. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). Lung cancer. 2020 May;143:27–35. doi: 10.1016/j.lungcan.2020.03.009
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113–125. doi: 10.1056/NEJMoa1713137
   PubMed Web of Science ®Google Scholar
• Garcia-Murillas I, Chopra N, Comino-Méndez I, et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol. 2019 Oct 1;5(10):1473–1478. doi: 10.1001/jamaoncol.2019.1838
   PubMed Web of Science ®Google Scholar
• Zhou Q, Zhang XC, Chen ZH, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2011 Aug 20;29(24):3316–3321. doi: 10.1200/JCO.2010.33.3757
   PubMed Web of Science ®Google Scholar
• Li X, Cai W, Yang G, et al. Comprehensive analysis of EGFR-Mutant abundance and its effect on efficacy of EGFR TKIs in advanced NSCLC with EGFR mutations. J Thorac Oncol. 2017 Sep;12(9):1388–1397.
   PubMed Web of Science ®Google Scholar
• Del Re M, Bordi P, Rofi E, et al. The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response. Br J Cancer. 2018 Nov;119(10):1252–1258.
   PubMed Web of Science ®Google Scholar
• Li JY, Ho JC, Wong KH. T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer. Oncotarget. 2018 Jun 15;9(46):27929–27939. doi: 10.18632/oncotarget.25332
   PubMedGoogle Scholar